医学
阿达木单抗
英夫利昔单抗
葡萄膜炎
危险系数
内科学
四分位间距
回顾性队列研究
依那西普
视网膜血管炎
优势比
外科
黄斑水肿
胃肠病学
类风湿性关节炎
血管炎
疾病
视力
置信区间
眼科
作者
G. Maalouf,Anaïs Andrillon,M. Leclercq,P. Sève,P. Bielefeld,J. Gueudry,Thomas Sené,Chérif Titah,T. Moulinet,Bénédicte Rouvière,Damien Sène,Anne-Claire Desbois,Fanny Domont,Sara Touhami,T. Thibault,Carolla El Chamieh,P. Cacoub,Laurent Kodjikian,Lucie Biard,Bahram Bodaghi,David Saadoun
标识
DOI:10.1016/j.ajo.2022.02.002
摘要
To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA).Observational retrospective multicenter study.A total of 330 patients (median age, 36 years; interquartile range, 27-54), 45.2% men) with sight-threatening NIU (ie, retinal vasculitis and/or macular edema) treated with anti-tumor necrosis factor [TNF]-α agents (IFX intravenously at 5 mg/kg at weeks 0, 2, 6, and every 4 to 6 weeks or ADA subcutaneously at 80 mg, then 40 mg every 2 weeks). Data were obtained retrospectively from patients' medical records. Main outcome measures were relapse rate, complete response of NIU, corticosteroid sparing effect, and safety.Main etiologies of uveitis included Behçet disease (27%), idiopathic juvenile arthritis (5.8%), and sarcoidosis (5.5%). The estimated relapse rate at 6 months after introduction of biological agents was 13% (95% CI = 0.009-0.16). IFX was associated with less relapse risk than ADA (hazard ratio [HR] = 0.52, 95% CI = 0.36- 0.77, P = .001). ADA and IFX were comparable in terms of complete response rate of NIU as well as corticosteroid-sparing effect. Behçet disease was associated with higher odds of complete response (HR = 2.04, 95% CI = 1.16 -3.60, P = .01] and lower relapse rate (HR = 0.53, 95% CI = 0.33-0.85, P = .009) than other causes of NIU with anti-TNF-α agents.In sight-threatening NIU, IFX seems to be associated with a lower relapse rate than ADA.
科研通智能强力驱动
Strongly Powered by AbleSci AI